{"disease":{"id":"severe-chronic-obstructive-pulmonary-disease","name":"Severe chronic obstructive pulmonary disease","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":4,"pipeline_drug_count":0,"trial_count":1},"drugs":{"marketed":[{"drug_id":"budesonide","indication_name":"Severe chronic obstructive pulmonary disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pulmicort Respules","generic_name":"BUDESONIDE","company_name":"AstraZeneca K.K.","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":"2800","mechanism":""},{"drug_id":"roflumilast","indication_name":"Severe chronic obstructive pulmonary disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Daliresp","generic_name":"ROFLUMILAST","company_name":"Arcutis","drug_phase":"marketed","molecular_target":"cAMP-specific 3',5'-cyclic phosphodiesterase 4D","drug_class":"Phosphodiesterase 4 Inhibitor [EPC]","quality_score":63,"revenue":null,"mechanism":"Daliresp works by blocking an enzyme called phosphodiesterase 4, which helps reduce inflammation in the body."},{"drug_id":"formoterol","indication_name":"Severe chronic obstructive pulmonary disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Foradil","generic_name":"FORMOTEROL","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"beta2-Adrenergic Agonist","quality_score":56,"revenue":null,"mechanism":"Foradil works by stimulating the beta-2 adrenergic receptor to relax airway muscles and improve breathing."},{"drug_id":"daxas","indication_name":"Severe chronic obstructive pulmonary disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Daxas","company_name":"AstraZeneca","drug_phase":"phase_2","molecular_target":"cAMP-specific 3',5'-cyclic phosphodiesterase 4A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B, cAMP-specific 3',5'-cyclic phosphodiesterase 4D","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02155660","title":"Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2255,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT02138916","title":"Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1656,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT07363694","title":"A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":1156,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT06252805","title":"Severe Prospective Observational COPD Catalonia","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":450,"lead_sponsor_name":"Ferran Morell","has_results":false},{"nct_id":"NCT03745547","title":"An Exploratory, Observational, Non-interventional, Open Label, Remote Pilot Study to Assess Adherence in COPD Subjects","phase":"","overall_status":"COMPLETED","enrollment_count":184,"lead_sponsor_name":"Spire, Inc.","has_results":false},{"nct_id":"NCT07402551","title":"Phase II Study of RC1416 Injection in COPD","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Nanjing RegeneCore Biotech Co., Ltd.","has_results":false},{"nct_id":"NCT05259280","title":"Observational Study of the Wellinks Solution Impact on Quality of Life and Clinical Outcomes in Patients With COPD","phase":"NA","overall_status":"COMPLETED","enrollment_count":153,"lead_sponsor_name":"Convexity Scientific Inc","has_results":false},{"nct_id":"NCT06175351","title":"Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD).","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":80,"lead_sponsor_name":"Mabwell (Shanghai) Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT03398772","title":"Effects of a Comprehensive Health Coaching Program in Advanced Chronic Obstructive Pulmonary Disease.","phase":"NA","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Taipei Medical University","has_results":false},{"nct_id":"NCT05199987","title":"Breathing Control Exercises in Patients With Chronic Obstructive Pulmonary Disease.","phase":"NA","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","has_results":false},{"nct_id":"NCT05222295","title":"The Effectiveness Pulmonary Telerehabilitation and Cognitive Telerehabilitation in COPD Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"Saglik Bilimleri Universitesi","has_results":false}],"total":11},"guidelines":[],"source":"Drug Landscape verified database"}